Divi's Laboratories Limited is incorporated back in 1990 and headquartered in Hyderabad, Telangana, India. This company, at its initial stage of the foundation, was named as Divi's Research Centre and later on in 1994 was changed to Divi's Laboratories Limited. This company is responsible for manufacturing and selling APIs or active pharmaceutical ingredients along with intermediates for generics. This is carried on in India, other parts of Asia, US, Europe and several other parts of the world.
It offers the different unit for building compounds like several carotenoids inclusive of beta-carotene, astaxanthin, canthaxanthin, lycopene, and apocarotenol. Other than this it also offers groups for building protects amino acids like FMOC, BCZ and BOC as well as for chiral ligands and peptide and nucleotides.
Apart from this, it also customizes the synthesis of several active pharmaceutical ingredients along with advanced forms of discovered compounds for other pharmaceutical companies. It also offers full-time contract-based research on development processes to identify new compounds.
Between the years 1991-1993, Divi's developed multiple bulk actives and other intermediates products for several other manufacturing companies. It received its ISO-9002 certification with compliance to SGS-Yarsley belonging to the UK, back in 1997. With the following two years, in 1999, the company received a Certificate of Suitability from the European Directorate for the production of Naproxen.
For the company's system of occupational health and safety management, it received the OHSAS-18001 certificate. It was given to them by BVQI from London in 2001. In the year 2002, Divi's set up their Unit number II, a manufacturing facility in Chippada. In the following year in 2003, the company inaugurated a new research centre in Vizag, named DRC-Vizag. This was built for fundamental research in specific core segments.
In the year 2004, Rs 3035.21 lakh was invested by Divi's for adding machines to both of their units in Unit-I (Choutuppal) and Unit-II (Chippada), and this was accounted for in their capital expenditure. In 2006, it received an approval letter from the Ministry of Commerce in India. This was for setting up a Special Economic Zone for multiple pharma based ingredients at Chippada, Vizag which led the company to invest Rs 200 crore.
During the year 2008-09, the company's portfolio added a total of 9 products. Four of these nine products consisted of generic APIs, and the rest belonged to intermediates and custom synthesis of APIs. Another seven products were added to the company portfolio in 2009-2010. Out of these seven products, 2 were generic APIs along with intermediates, while the rests were intermediates and custom synthesis APIs. During the year 2012-13, the company went on to add another nine products out of which three of these were generic APIs along with intermediates, and the rest six were custom synthesis APIs and intermediates.
On 19 February 2016, the company went through an inspection by US-FDA for its second unit in Chapada, Bhemunipatam near Vizag and was this event was successful which happened without any observation. In 2017, on 18 November, the company announced that it had received EIR (Establishment Inspection Report) from FDA (US) for their second unit in Vizag. On 16 May 2018, Divi's Laboratories stated that their Unit-I in Telangana was under the inspection of the US-FDA starting from 14 May 2018 to 16 May 2018. The review conducted was a cGMP general inspection done by the FDA.
The company is one of the biggest pharmaceutical companies in the country, which currently has a portfolio of 120 products. It has presently products belonging to multiple therapeutic aspects. It has a total of four manufacturing units with a developing market presence in several countries. Their first facility is located in Yadadri Bhuvanagiri District; Telangana consists of 11 blocks for multipurpose production along with finishes product spaces for APIs.
How Divi’s Laboratories, is categorised as a Pharmaceutical and Health care Sector, and Pharmaceutical Industry :
The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
Divi's Laboratories is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
Divi’s Laboratories, Competitors and Sector Peers:
Alembic Pharmaceuticals Ltd. ALEPHA
Alkem Laboratories Ltd. ALKLAB
Alpa Laboratories Ltd. ALPLAB
Ambalal Sarabhai Enterprises Ltd. AMBSAR
AstraZeneca Pharma India Ltd. ASTZEN
Bafna Pharmaceuticals Ltd. BAFPHA
Bajaj Healthcare Ltd. BAJHEA
Concord Drugs Ltd. CONDRU
Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
Divi's Laboratories Ltd. DIVIL
Dr. Reddy's Laboratories Ltd. DR
GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
Glenmark Pharmaceuticals Ltd. GLEPHL
IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
Lincoln Pharmaceuticals Ltd. LINPHA
Madhuveer Com 18 Network Ltd. TOHPHA
Mahavir Advanced Remedies Ltd. INDAME
Makers Laboratories Ltd. MAKLAB
Natural Capsules Ltd. NATCAP
Ranbaxy Laboratories Ltd. RANLAB
Sharon Bio-Medicine Ltd. SHAPHA
Sun Pharmaceutical Industries Ltd. SUN28
Zenith Healthcare Ltd. ZENHEA
Crude's Rise, Rupee's Fall Looming Risks For Markets But These 8 Stocks May Reap BenefitMoneycontrolNewsBotDec 30, 2020 6:43 AM
Buy Divi's Laboratories; Target Of Rs 4425: ICICI DirectMoneycontrolNewsBotDec 17, 2020 6:03 AM
Divi's Laboratories Shares Climb 3%; Stock Crosses Rs 1 Lakh Crore M-cap MarkMoneycontrolNewsBotDec 7, 2020 7:53 AM
Buy Divis Laboratories: Target Of Rs 4175: SharekhanMoneycontrolNewsBotNov 24, 2020 8:08 AM
Sensex seen at 45,500; these 5 stocks gave positive surprise with Q2 earnings: ICICI DirectMoneycontrolNewsBotNov 11, 2020 5:13 AM
Buy Divis Laboratories: target of Rs 3800: SharekhanMoneycontrolNewsBotNov 10, 2020 5:48 AM
Buy Divi’s Laboratories; target of Rs 3900: Motilal OswalMoneycontrolNewsBotNov 9, 2020 7:23 AM
Accumulate Divi's Laboratories; target of Rs 3515: Dolat Capital MarketMoneycontrolNewsBotNov 9, 2020 5:33 AM
Buy Divi's Laboratories; target of Rs 4205: ICICI DirectMoneycontrol